GeneDx Holdings Launches Patient Access Program for Pediatric Epilepsy Diagnosis Improvement

Breaking Barriers in Pediatric Epilepsy Diagnosis: GeneDx Launches Patient Access Program

GeneDx Holdings, a prominent player in genomic insights, recently announces the launch of a Patient Access Program aimed at addressing the significant diagnostic delays faced by children with epilepsy. In collaboration with industry partners Biogen, Praxis Precision Medicines, and Stoke Therapeutics, GeneDx seeks to transform the diagnostic landscape for pediatric epilepsy, where families often endure a protracted journey lasting 5 to 8 years before obtaining a definitive genetic diagnosis. The initiative highlights the pressing need for whole exome sequencing, given that conventional gene panels only cover a fraction of the over 700 known genes associated with seizures.

The Patient Access Program is designed to enhance access to whole exome sequencing, a powerful diagnostic tool that has demonstrated a genetic diagnosis yield of nearly 25% in seizure patients, markedly higher than the 19% yield from traditional gene panels. The endorsement of exome testing as a first-line approach for unexplained epilepsy by the National Society of Genetic Counselors and the American Epilepsy Society underscores the validity of this approach. However, despite these recommendations, many patients still face disparities in access, which can delay critical diagnoses and treatment options. GeneDx aims to bridge this gap, ensuring that more families can benefit from cutting-edge genomic testing.

As part of this initiative, GeneDx plans to enrich its extensive database of genomic results, currently exceeding 700,000 exome and genome sequences. This growing repository will not only facilitate improved diagnostic capabilities but also contribute crucial insights into gene-disease relationships related to seizure disorders. Melanie Duquette, the Chief Growth Officer of GeneDx, emphasizes that understanding the genetic basis of epilepsy—affecting around half a million children under 18 in the U.S.—is vital for developing personalized treatments. By improving access to genetic testing, the program aims not only to provide clarity for patients but also to support ongoing research that could lead to innovative therapies in the biopharma sector.

In addition to enhancing access to genetic testing, GeneDx’s initiative is a critical step toward equitable healthcare for children with epilepsy. The program's focus on whole exome sequencing aligns with the growing recognition of the need for comprehensive genetic testing in pediatric populations, which often experience unique challenges in diagnosis and treatment. As the healthcare landscape evolves, such initiatives become essential in ensuring that all patients receive timely and effective care.

The launch of the Patient Access Program by GeneDx represents a significant advancement in the understanding and treatment of pediatric epilepsy. By leveraging partnerships and genomic innovations, GeneDx not only aims to improve diagnostic outcomes but also to pave the way for a future where personalized medicine can profoundly impact the lives of children suffering from this condition.